

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 03/082327 A2

(51) International Patent Classification⁷: **A61K 39/00**, (74) Agent: **HUYGENS, Arthur, V.**; Octrooibureau HUYGENS, P.O. Box 86, NL-3400 AB IJsselstein (NL).

(21) International Application Number: PCT/EP03/03353

(22) International Filing Date: 28 March 2003 (28.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02076276.1 28 March 2002 (28.03.2002) EP
03075383.4 10 February 2003 (10.02.2003) EP

(71) Applicant (for all designated States except US): **BRENTAG BIOSECTOR A/S** [DK/DK]; Elsenbakken 23, DK-3600 Frederikssund (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **REIMANN, Hansjörg** [DE/DE]; Ringstrasse 88, 89081 Ulm-Lehr (DE). **SCHIRMBECK, Reinhold, Alois** [DE/DE]; Danzigerstrasse 13, 36381 Krumbach (DE). **LINDBLAD, Erik, B.** [DK/DK]; Frederiksberg Alle 19 B, DK-1820 Frederiksberg (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINED DNA/PROTEIN VACCINE COMPOSITIONS

(57) Abstract: The present invention relates to a novel, combined DNA/Protein antigen vaccine composition comprising nucleic acid molecules and a mineral-based, negatively charged adjuvant, so as to enhance the immunogenicity of the DNA vaccine efficiently enhancing not only plasmid DNA vaccines but also providing a novel strategy for immunogenic, multivalent combined protein/DNA vaccine delivery. Preferred adjuvants are aluminium or calcium salts, in particular aluminium phosphate.

WO 03/082327 A2

Combined DNA/Protein Vaccine Compositions

Field of the invention

5 The present invention relates to novel, combined DNA/Protein vaccine compositions comprising at least one nucleic acid molecule encoded antigen and at least one protein antigen adjuvanted in a mineral-based adjuvant so as to enhance the immunogenicity of both in a single vaccine formulation.

Background of the invention

10 DNA vaccination is an important novel immunization strategy to specifically prime humoral and cellular immune responses (S. Gurunathan et al., *Annu Rev. Immunol.* (2000) 18:927-74). With DNA vaccines based on injection of nucleotides alone 50-100 µg nucleotide is required to elicit a potent immune response against the antigen encoded by
15 the DNA. It is not known how large a proportion of the DNA that is *de facto* transcribed into protein and it is not clear how much protein that it subsequently gives lead to. It has been shown, however, that no or barely detectable immune responses are detected when <10 µg plasmid DNA is injected into mice.

 Currently, DNA vaccines are not yet on the market. Limitations that prevent the
20 introduction of DNA vaccination into clinical practice include the conspicuous absence of techniques that can deliver low doses of a DNA vaccine in a sufficiently immunogenic form to a wide range of animals and to man. It will be clear that the development of techniques which would lead to the elicitation of a potent immune response after administration of significantly lower doses of DNA nucleotide would attract both scientific and economic
25 interest among vaccine producers.

 In recent literature various adjuvants have been proposed to enhance the immunogenicity of DNA vaccines. For example, the interrelated references WO 00/02591, WO 98/35562, and S. Wang et al., *Vaccine* 18:1227-1235 (2000) disclose vaccine formulations comprising nucleic acid molecules and an aluminium phosphate-based or
30 calcium phosphate-based adjuvant provided in a biologically effective concentration so as to improve induction of an immune response subsequent to vaccination. The formulations with calcium- or aluminum phosphate adjuvants prior to injection have been shown to facilitate delivery of DNA vaccines, since antibody titers are increased by 10- to 100-fold and the immunogenic dose of DNA is decreased by 10-fold. Although the mechanism by

which aluminium phosphate or aluminium hydroxyphosphate exerts this adjuvant effect is not clear, the adjuvants have an extensive record from use in practical vaccination.

WO 99/51269 discloses a DNA vaccine containing a naked DNA incorporating and expressing *in vivo* a nucleotide sequence encoding an antigenic polypeptide and at least an adjuvant compound selected from the class of (meth)acrylic polymers and copolymers of maleic anhydride and alkenyl derivatives, preferably a carbomer or an EMA®.

WO 02/03961 discloses a nucleic acid delivery system comprising nucleic acid molecules encapsulated in biodegradable microspheres, suitable for delivering DNA vaccines, which comprises an adjuvant for modulating the immunostimulatory efficacy said adjuvant comprising an aminoalkyl glucoaminide-4-phosphate (AGP).

WO99/30733 discloses a method to enhance an immune response based on a combination of polynucleotide and polypeptide. Pharmaceutical compositions comprising DNA + polypeptide may contain a specially prepared aluminium hydroxide ($\text{Al}(\text{OH})_3$). The protein antigen was adsorbed onto aluminium hydroxide (Example 8) and subsequently co-acervated with polycaprolactone to create a complex form with slow-release of antigen from the specially treated $\text{Al}(\text{OH})_3$. This complex was then mixed with the DNA in the ratio 2 μg protein to 10 μg DNA prior to use. No other approaches to adjuvantation of the peptide-nucleotide combination using other mineral-based adjuvants were investigated.

WO 97/28818 discloses vaccinations and vaccines comprising a nucleic acid encoding a first epitope and a peptide encoding a second epitope, in particular *in vitro* transfection of APC's (Antigen Presenting Cells) with DNA encoded antigen (and not muscular tissue which is the normal target tissue for DNA immunization) and the simultaneous presence of peptide antigen as well as DNA encoded and transcribed antigen in APC's was demonstrated. Several vectors and delivery systems were discussed and a speculation was made (p. 42) on the possible use of a wide range of adjuvants, but no experimental data for the use of any adjuvant was provided.

Conventional vaccines allow the combination of different antigens, but only within the group of either adjuvanted vaccine components or within the group of non-adjuvanted live-attenuated vaccine relevant organisms. The former group which is adjuvanted by mineral salts primarily gives lead to a Th2 response which is protective for the mentioned diseases, whereas similar adjuvantation could have an inhibitory effect on the immune response necessary for protection against the live attenuated vaccine components (E.B. Lindblad et al., *Infect. Immun.* 65(2):623-629 (1997)). This dichotomy currently limits the possibilities of making combination vaccines where diseases from the

two groups, respectively, are represented. The diseases covered by the live attenuated vaccines are often requiring a Th1 type immune response as protecting against these diseases does not depend upon an antibody response alone.

There is still a need for further investigation in order to improve the immunogenicity of DNA vaccines. It is noted in this connection that as far as the inventors are aware the possibility of combining DNA nucleotide-based vaccines with conventional protein or adsorbed protein-based vaccines for establishing an efficient combination of these two technologies has hitherto not been explored, especially not in relation to the use of negatively-charged mineral-based adjuvants.

The DNA vaccine technology has the potential of inducing a Th1 type response necessary for protection against those diseases which are at present prevented by the group of live attenuated vaccines. The present invention provides a combination of at least one DNA vaccine with one or more classically adjuvanted Th2 stimulating vaccines, thereby overcoming such limitations of preparing an extended programme of combination vaccines.

Summary of the invention

The present invention provides a combined DNA/Protein antigen vaccine composition suitable for administration to a vertebrate host, including man, which comprises:

- (a) a polynucleotide vaccine component comprising at least one polynucleotide encoding at least one antigen, such that introduction of said formulation into said vertebrate host results in expression of a biologically effective amount of said antigen or antigens so as to induce a prophylactic or therapeutic immune response;
- (b) a protein antigen vaccine component comprising at least one protein antigen selected from the group of model protein antigens and vaccine protein antigens; and
- (c) a mineral-based, negatively charged adjuvant.

In a preferred embodiment of the invention said mineral-based, negatively charged adjuvant is an adjuvant selected from the group of aluminium phosphate-based and aluminium hydroxyphosphate-based adjuvants.

In another embodiment of the invention said mineral-based, negatively charged adjuvant is an adjuvant selected from the group of calcium phosphate-based and calcium hydroxyphosphate-based adjuvants.

Suitable polynucleotide vaccine components which can be used in the vaccine composition according to the invention include components from vaccines where the classical aluminium adjuvants are considered inadequate to elicit protection, for example intracellular parasitic bacteria like *Mycobacterium* sp. and *Leishmania* sp., and viruses like
5 cytomegalovirus (CMV), HTLV-I, HIV, hepatitis C and D, influenza, measles, rubella, and tumour-associated antigens.

Suitable model protein antigens may range from acidic IEP proteins, such as bovine serum albumin and human serum albumin, to basic IEP proteins, such as lysozyme.

10 Suitable vaccine protein antigens include but are not limited to detoxified toxins as well as other vaccine relevant antigens at present used in conventional vaccines against e.g. tetanus, diphtheria, botulinus poisoning, pertussis, inactivated poliomyelitis, hepatitis A and B, and the like.

 In yet another preferred embodiment said mineral-based, negatively charged
15 adjuvant is pre-incubated by said at least one protein antigen vaccine component prior to being formulated with said polynucleotide vaccine component to a vaccine composition according to the present invention.

 In a further aspect of the invention the use of a mineral-based, negatively charged adjuvant is provided as a component in a combined DNA/Protein based vaccine
20 composition as herein defined.

 In another aspect of the invention a kit is provided comprising a vaccine composition as defined above, in a unit dose form for administration to a vertebrate recipient, including man.

 In yet another aspect of the invention a method of inducing an immune
25 response in a vertebrate host is provided which comprises introducing a vaccine composition as defined above into said vertebrate host.

 These and other embodiments of the present invention will be outlined in more detail in the following detailed description.

30 Brief description of the drawing

 Figure 1 shows that the codelivery of plasmid DNA and protein vaccines in aluminum phosphate (AlPO_4) increases Ab titer against both antigens. BALB/c mice were vaccinated intramuscularly by single injection of the combination of 5 μg recombinant (HBcAg or HBsAg) particles and 50 μg plasmid DNA encoding HBsAg or HBcAg (pCI/S,
35 pST/C). Vaccines containing either rHBcAg and pCI/S (group 1,2) or rHBsAg and pST/C

(group 3,4) were delivered alone (group 1,3) or formulated with AlPO_4 adjuvant (group 2,4). Sera were obtained 4 weeks post-immunization and tested for anti-HBsAg (left panel) and anti-HBcAg (right panel) antibodies by ELISA. The mean antibody titers of 3 individual mice are shown.

5

Definitions

The term "polynucleotide vaccine" (PNV) which is identical to "DNA vaccine", as used herein, is meant to indicate a DNA vector containing a gene encoding a viral, bacterial, parasitic or tumor antigen which has been shown to express that respective antigen subsequent to administration to the vertebrate, for example by intramuscular injection.

The term "model protein antigen" as used herein is meant to define a protein which is not derived from an infectious microorganism which may cause one or more diseases. Hence a model protein antigen is not included in a vaccine preparation with the aim of eliciting a protective immune response towards the model protein itself.

The term "conventional vaccines", as used herein, is meant to define well-established vaccines, whether they are based on (1) live, attenuated vaccine components (not adjuvanted), or (2) killed inactivated vaccine components, killed whole cells, purified subunit or peptide components (which are adjuvanted), using e.g. mineral adjuvants

The term "vaccine protein antigen" as used herein, refers to an antigen, regardless whether it is a protein-containing cell fragment, a purified protein, a synthetic peptide or whether in its nature it consists of amino acids only or of amino acids in combination with other biological molecules, like carbohydrates or lipids, derived from an infectious organism against which the vaccine is intended to protect. The purpose of including the vaccine protein antigen is to induce specific and protective immunity towards the infection caused by the organism that the vaccine protein relevant was derived from.

The term "adjuvant", as used herein, refers to one or more compounds that enhance the immune response against the antigenic components of the vaccine formulation or helps delivering the nucleotide or provides a stimulative effect for the immune response to transcription products of the injected DNA nucleotides.

The term "negatively charged mineral-based phosphate adjuvant", as used herein, refers to preformed aluminium phosphate or aluminium hydroxyphosphate gel adjuvants, and the like, which are characterized by having an acidic point of zero charge (PZC). It also refers to a formulation by which preformed aluminium hydroxide adjuvant (which normally has an alkaline PZC) after its formation is incubated with phosphate ions

to form a complex with these by which process it also - subsequently - achieves an acidic PZC. It also refers to calcium phosphate or calcium hydroxyphosphate based adjuvants.

The term "point of zero charge" or "PZC", as used herein refers to the specific pH value at which a given mineral-based adjuvant has no net charge. As such the PZC is analogous to the isoelectric point (IEP) of a protein as known from protein chemistry. At pH values above the PZC the net charge of the mineral-based adjuvant is negative and below the PZC the net charge of the mineral-based adjuvant is positive.

Detailed description of the invention

10 The present invention is based on the surprising finding, after extensive research and experimentation, that aluminium phosphate or aluminium hydroxyphosphate-mediated enhancement of the immunogenicity of DNA vaccines was further improved by pre-incubating aluminium phosphate or aluminium hydroxyphosphate with at least one suitable protein. It was also found that aluminium phosphate and aluminium hydroxy-
15 phosphate and their calcium counterparts can be used to combine protein- and DNA-based vaccination to prime an enhanced and differentiated specific immunity.

The invention relates in one aspect to a novel vaccine formulation comprising nucleic acid molecules and a mineral-based, negatively charged adjuvant delivered in a biologically effective concentration so as to promote the effective induction of an immune
20 response directed towards one or more specific antigens encoded by the nucleic acid molecule(s). According to this aspect the adjuvant, when delivered in conjunction, e.g. pre-incubated or pre-mixed with a suitable protein, seems to have a different appearance as compared to the original vaccine formulations on which this improvement is based which have been extensively described, *inter alia* in WO 00/2591, the disclosure of which is
25 incorporated herein by reference. Apart from the improvement defined above, any aspect of said disclosure including definitions, preparation of the pharmaceutical formulations, selection and amounts of ingredients, methods of inducing an immune response in an vertebrate host using the pharmaceutical formulations, way of delivery of the formulations to the vertebrate host, the diseases or disorders to be treated by the formulations, etc.,
30 apply equally to the present invention.

The present invention is further based on the surprising finding that the enhancement is mediated by the negatively charged mineral-based phosphate adjuvant (as exemplified by, but not limited to aluminium phosphate and aluminium hydroxy phosphate), with a suitable protein, as exemplified by either a model protein, such as an
35 acidic IEP protein, for example bovine serum albumine (BSA) having low adsorption

affinity, or a basic IEP protein, for example hen egg lysozyme (HEL) having high adsorption affinity, or, alternatively, a vaccine-relevant protein antigen, as exemplified by - but not limited to - two vaccine-relevant antigens of hepatitis B virus (HBV), i.e. its envelope protein (hepatitis B surface antigen, HBsAg) and its nucleoprotein (hepatitis B core antigen, HBcAg). Accordingly, a protein antigen, whether or not intended to raise protective immune responses against itself, can be suitably and advantageously co-delivered with DNA vaccines formulated in aluminium phosphate, aluminium hydroxyphosphate, or another suitable negatively charged mineral adjuvant.

It was further found that AlPO_4 is particularly suitable as an adjuvant to formulate a vaccine composition that delivers expression plasmid-encoded antigens together with recombinant protein antigens. The vaccine composition combines (i) the adjuvant effect of AlPO_4 , (ii) the adjuvant effect of plasmid DNA, (iii) the enhanced immunogenic delivery of a DNA vaccine by AlPO_4 , and (iv) the potent co-priming of multispecific, humoral and cellular immune responses to a variety of antigens that usually is achieved only by immunization with vaccines containing live, attenuated or killed pathogens.

When analyzing the priming of murine humoral and CTL responses to vaccine-relevant antigens formulated in aluminium-based adjuvants, no boosting injections were given to exclusively determine the potency of the vaccine formulations under study in priming CTL and T cell-dependent immune responses. (It will be understood that boosting injections are not excluded from the the present invention).

It is known that plasmid DNA and proteins with an acidic IEP adsorb efficiently onto $\text{Al}(\text{OH})_3$, but not to AlPO_4 [J.B. Ulmer *et al.*, *Vaccine* (1999) 18:18-28; S.J. Seeber *et al.*, *Vaccine* (1991) 9:201-203]. An immunogenic delivery of DNA vaccines with conventional $\text{Al}(\text{OH})_3$ adjuvant has not been achieved while $\text{Al}(\text{OH})_3$ is widely used to deliver protein antigens in immunogenic form. Without being bound to any theory, the present inventors believe that the high content of phosphate in the DNA strand may give lead to the very high binding affinity to $\text{Al}(\text{OH})_3$ and that this binding impairs the subsequent transcription of the protein antigen encoded by the DNA. A "depot effect", i.e. the slow release of antigen *in situ* combined with an immune-stimulating effect of the aluminium salt, has often been proposed to underlie the adjuvant activity. The lack of adsorption of plasmid DNA onto AlPO_4 (but not $\text{Al}(\text{OH})_3$) seems to be an essential prerequisite for its ability to deliver DNA vaccines in an adequate and functional form. When low doses of a "naked" DNA vaccine are injected i.m. without adjuvants, specific priming of CTL, but not of serum antibody responses is observed [W. Böhm *et al.*, *J.*

Immunol. Methods (1996) 193:29-40]. Delivery of a DNA vaccine by AlPO_4 did not enhance its ability to prime specific, polarization of the response against the individual components of the vaccine. The antigens encoded by DNA vaccines would preferentially prime Th1 immunity while the antigens formulated into the AlPO_4 as recombinant proteins would preferentially induce Th2 immunity. This is clearly shown in Figure 1 where one can see that the DNA-derived antibody response is biased towards the IgG2a subclass, indicative of Th1 immunity, whereas the protein-derived antibody response is biased towards the IgG1 subclass, indicative of Th2 immunity. This does not take into account intrinsic features of an antigen that can drive the polarization of the immune response they induce into a Th1 or Th2 bias independent of the locally prevailing cytokine milieu [P. Riedl *et al.*, *J. Immunol.* (2002) 168:4951-4959; J. Reimann and R. Schirmbeck, *Dev. Biol.* (2000) 104:15-24]. However, the key point is that the vaccine delivery strategy according to the present invention supports the formulation of a single vaccine composed of very different types of vaccine constructs that prime *in situ* a diverse spectrum of immune responses differing in specificity and in the repertoire of specific effector functions they can mediate, i.e., a differentiated Th1 to the DNA encoded antigen, including a CTL response, and a Th2 response to the protein antigen.

Experimental vaccines were formulated in which low doses (1-5 $\mu\text{g}/\text{mouse}$) of antigen-encoding plasmid DNA together with low doses of either a model protein antigen (BSA), or a vaccine-relevant protein antigen (HBsAg or HBcAg) was mixed with aluminium phosphate or aluminium hydroxide. The immune responses elicited by this combination vaccine against the protein antigen adsorbed to aluminium phosphate were enhanced in the presence of the DNA vaccine, and did not interfere with immune responses against the antigen encoded by the DNA vaccine.

To be more specific, low doses of different DNA vaccines formulated with AlPO_4 induced enhanced humoral responses and supported priming of MHC class I-restricted cellular immunity. Different proteins mixed with the plasmid DNA vaccine in the AlPO_4 formulation did not impair its immunogenicity. Co-injection of two different, vaccine-relevant antigens in the same AlPO_4 formulation, one as a DNA vaccine, the other as a recombinant protein, elicited polyvalent, humoral and cellular immune responses to all antigens delivered. The isotype profiles of the induced humoral responses and the cytokine profiles of the specifically primed T cell responses indicated that the combined vaccines supported co-priming of Th1- and Th2-biased, as well as differentiated responses.

Therefore, protein antigen-containing mineral-based, negatively charged adjuvants, such as aluminium phosphate and for example also aluminium hydroxy-phosphate can efficiently enhance not only plasmid DNA vaccines but also provides a novel strategy for immunogenic, multivalent combined protein/DNA vaccine delivery.

5 The invention is further illustrated by the following examples which, however, are not intended to limit the invention in any respect.

Experimental

Immunization of BALB/c mice with protein- or DNA-based vaccines was
10 chosen as the preclinical model since a significant amount of the preclinical experience obtained with novel vaccination approaches has been generated in this species.

Standard immunization procedures were used based on the intramuscular injection of either 5, 50 or 100 µg plasmid DNA vaccines, or 0.5-5 µg protein antigen.

15 1. **Mixing a model protein (antigen) together with a plasmid DNA vaccine to Al phosphate or Al hydroxyphosphate enhances the immunogenicity of the latter**

BALB/c mice were immunized i.m. with 5, 50 or 100 µg pCI/S plasmid DNA (encoding the small HBsAg).

The DNA was delivered:

- 20 - without vehicle (as "naked" plasmid DNA)
 - with aluminium phosphate
 - without protein antigen added
 - with (A) BSA or (B) HEL added

The antibody response was determined 4 weeks after a single immunization.

25

(A) BSA system (see Table 1)

Table 1

group	pCI/S DNA vaccine (μ g/mouse)	protein (BSA)	aluminium phosphate	anti-HBsAg serum antibody titer mIU/ml
1	5	-	-	<10
2	50	-	-	978
3	100	-	-	1898
4	5	-	+	458
5	50	-	+	2889
6	5	+	-	<10
7	50	+	-	2756
8	5	+	+	1789
9	50	+	+	4572
10	-	+	-	<10

5 (B) HEL system (see Table 2)

Table 2

group	pCI/S DNA vaccine (μ g/mouse)	protein (HEL)	aluminium phosphate	anti-HBsAg serum antibody titer mIU/ml
1	5	-	-	<10
2	50	-	-	613
3	100	-	-	965
4	5	-	+	549
5	50	-	+	2790
6	5	+	-	<10
7	50	+	-	1473
8	5	+	+	753
9	50	+	+	3317
10	-	+	-	<10

10 These results allow the following conclusions:

- A dose-dependent antibody response against a DNA nucleotide encoded antigen is induced by a single i.m. injection of the pCI/S DNA vaccine.
- The immunogenicity of the pCI/S DNA vaccine is enhanced when it is mixed before i.m. delivery with aluminium phosphate or aluminium hydroxyphosphate.

- When protein antigens (BSA) are mixed with aluminium phosphate or aluminium hydroxyphosphate the immunogenicity of the pCI/S DNA vaccine also mixed to aluminium phosphate or aluminium hydroxyphosphate is strikingly enhanced.

5 2. Mixing a vaccine protein antigen and a plasmid DNA vaccine with Al phosphate

BALB/c mice were immunized i.m. with 5, 50 or 100 µg pCI/LC149 plasmid DNA (encoding a secreted, truncated variant of the HBV core antigen HBcAg).

The DNA vaccine was delivered:

- without vehicle (as 'naked' plasmid DNA)
- 10 - with aluminium phosphate
 - without protein antigen added
 - with HBsAg added

HBsAg (2 µg/mouse) was delivered.

- without vehicle (as 'naked' protein particles)
- 15 - with aluminium phosphate
 - without protein antigen added
 - with DNA vaccine added

The antibody response was determined 4 weeks after a single immunization.

The results are shown in Table 3 below.

20

Table 3

group	pCI/LC ₁₄₉ DNA vaccine (µg/mouse)	Protein antigen: HBsAg	aluminium phosphate	reciprocal anti- HBc/eAg endpoint antibody titer	anti-HBsAg serum antibody titer mIU/ml
1	5	-	-	<10	<10
2	50	-	-	10.000	<10
3	100	-	-	26.000	<10
4	5	-	+	2.500	<10
5	50	-	+	75.000	<10
6	5	+	-	<10	2187
7	50	+	-	10.000	3210
8	5	+	+	12.500	2630
9	50	+	+	120.000	3540
10	-	+	+	<10	2100

These results allow the following conclusions:


- A dose-dependent antibody responses is induced by a single i.m. injection of the pCI/LC₁₄₉ DNA vaccine; the immunogenicity of the DNA vaccine is enhanced when it is mixed before i.m. delivery with aluminium phosphate or aluminium hydroxy-phosphate.
- Protein antigens (HBsAg) and DNA vaccines are mixed with aluminium phosphate or aluminium hydroxyphosphate prime polyvalent immune responses.

3. Adsorption of vaccine protein antigen (HBsAg) to Al phosphate / Al hydroxy-phosphate or Al hydroxide

In vitro experiments:

- i. 91 μ l = 450 μ g Al of either aluminium phosphate or aluminium hydroxide were incubated for 24 h at 4°C (under constant shaking) with 100, 50, 10, 5 or 1 μ g HBsAg in a total volume of 200 μ l; a parallel set of samples was incubated additionally with 50 μ g plasmid DNA.
- ii. the alum was spun down and supernatants were harvested.
- iii. HBsAg (Abbott AxSym HBsAg V2-kit (cat.no. 7A 10-22, Abbott, Wiesbaden, Germany) in supernatants (S/N) was measured by the Abbott ELISA.

The results are shown in the following graph.



HBsAg was readily detected in S/N of mixtures of antigen with aluminium phosphate (even when as low amounts as only 1 μ g HBsAg was mixed with the phosphate adjuvant) while no HBsAg was detectable after incubation with aluminium

hydroxide. There was no difference in HBsAg release when plasmid DNA was also mixed (together with HBsAg protein) to the aluminium adjuvant preparation.

These results allow the following conclusions.

- 5 - Aluminium phosphate and aluminium hydroxyphosphate do not adsorb HBsAg but aluminium hydroxide adsorbs HBsAg efficiently.
- Plasmid DNA in the applied quantities suitable for vaccination has no influence on the adsorption or non-adsorption of protein antigen to aluminium adjuvants.

Claims

1. A vaccine composition suitable for administration to a vertebrate host, including man, which comprises:

- 5 (a) a polynucleotide vaccine component comprising at least one polynucleotide encoding at least one antigen, such that introduction of said formulation into said vertebrate host results in expression of a biologically effective amount of said antigen or antigens so as to induce a prophylactic or therapeutic immune response;
- (b) a protein antigen vaccine component comprising at least one protein antigen selected from the group of model protein antigens and vaccine protein antigens; and
- 10 (c) a mineral-based, negatively charged adjuvant.

2. A vaccine composition according to claim 1 wherein said mineral-based negatively charged adjuvant is an aluminium salt or a calcium salt.

- 15 3. A vaccine composition according to claim 2 wherein said aluminium or calcium salt is selected from the group consisting of aluminium phosphate, aluminium hydroxyphosphate, phosphate-treated aluminium hydroxide, calcium phosphate, calcium hydroxyphosphate, and phosphate-treated calcium hydroxide.

- 20 4. A vaccine composition according to any one of claims 1 to 3 wherein said group of model protein antigens range from acidic IEP proteins to alkaline IEP proteins.

5. A vaccine composition according to any one of claims 1 to 4 wherein said group of vaccine protein antigens includes a surface protein or a core protein of HBV, a
- 25 de-toxified toxin from the bacteria *Clostridium tetani* (i.e. tetanus toxoid), a de-toxified toxin from the bacteria *Clostridium botulinus* (i.e. botulinus toxoid), and a de-toxified toxin from the bacteria *Corynebacterium diphtheriae* (i.e. diphtheria toxoid).

6. A vaccine composition according to any one of claims 1 to 4 wherein said
- 30 group of vaccine protein antigens includes protein antigens derived from inactivated poliovirus.

7. A vaccine composition according to any one of the preceding claims, wherein said mineral-based negatively charged adjuvant is preincubated or subsequently

mixed with said at least one protein antigen vaccine component prior to being formulated with said polynucleotide vaccine component.

8. A kit comprising a vaccine composition as defined in any one of the claims 1-7 in a unit dose form for administration to a vertebrate recipient, including man.

9. Use of a mineral-based, negatively charged adjuvant as a component in a combined DNA/protein-based vaccine composition as defined in any one of claims 1-7.




Fig. 1

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 2003/082327 A3

(51) International Patent Classification⁷: **A61K 39/00**,
39/39, 48/00

(74) Agent: HUYGENS, Arthur, V.; Octrooibureau HUY-
GENS, P.O. Box 86, NL-3400 AB IJsselstein (NL).

(21) International Application Number:
PCT/EP2003/003353

(22) International Filing Date: 28 March 2003 (28.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02076276.1 28 March 2002 (28.03.2002) EP
03075383.4 10 February 2003 (10.02.2003) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
4 March 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): **BRENTAG BIOSECTOR A/S** [DK/DK]; Elsenbakken 23, DK-3600 Frederikssund (DK).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **REIMANN, Hansjörg** [DE/DE]; Ringstrasse 88, 89081 Ulm-Lehr (DE). **SCHIRMBECK, Reinhold, Alois** [DE/DE]; Danzigerstrasse 13, 36381 Krumbach (DE). **LINDBLAD, Erik, B.** [DK/DK]; Frederiksberg Alle 19 B, DK-1820 Frederiksberg (DK).

(54) Title: COMBINED DNA/PROTEIN VACCINE COMPOSITIONS

(57) Abstract: The present invention relates to a novel, combined DNA/Protein antigen vaccine composition comprising nucleic acid molecules and a mineral-based, negatively charged adjuvant, so as to enhance the immunogenicity of the DNA vaccine efficiently enhancing not only plasmid DNA vaccines but also providing a novel strategy for immunogenic, multivalent combined protein/DNA vaccine delivery. Preferred adjuvants are aluminium or calcium salts, in particular aluminium phosphate.

WO 2003/082327 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/03353

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/00 A61K39/39 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, WPI Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 02591 A (MERCK & CO, INC.) 20 January 2000 (2000-01-20) cited in the application page 20, line 21 - line 27 examples claims	1-3,5,8, 9
Y	---	4,6
X	WO 99 30733 A (SMITHKLINE BEECHAM BIOLOGICALS S.A.) 24 June 1999 (1999-06-24) page 9, line 18 - line 27 claims	1-3,8,9
X	WO 97 28818 A (THEREXSYS LIMITED) 14 August 1997 (1997-08-14) page 42, line 7 - line 19 claims	1-3,8,9

	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

17 September 2003

Date of mailing of the international search report

25/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/03353

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 68259 A (G. LINDAHL) 16 November 2000 (2000-11-16) page 27, line 5 - line 8 page 29, line 7 - line 9 ---	4
Y	WO 93 24148 A (SMITHKLINE BEECHAM BIOLOGICALS (S.A.)) 9 December 1993 (1993-12-09) page 3, line 8 - line 12	6
A	---	7
A	S. WANG ET AL.: "Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminium phosphate." VACCINE, vol. 18, no. 13, 21 January 2000 (2000-01-21), pages 1227-1235, XP002234919 Guildford, GB cited in the application abstract page 1234, left-hand column, line 15 - line 21 -----	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/03353

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0002591	A	20-01-2000	AU 4973199 A	01-02-2000
			CA 2336992 A1	20-01-2000
			EP 1094844 A1	02-05-2001
			JP 2002520299 T	09-07-2002
			WO 0002591 A1	20-01-2000
			US 2002045594 A1	18-04-2002
WO 9930733	A	24-06-1999	AU 740729 B2	15-11-2001
			AU 1967899 A	05-07-1999
			BR 9814285 A	03-10-2000
			CA 2313005 A1	24-06-1999
			CN 1284883 T	21-02-2001
			WO 9930733 A1	24-06-1999
			EP 1037662 A1	27-09-2000
			HU 0100197 A2	28-05-2001
			JP 2002508333 T	19-03-2002
			NO 20003087 A	08-08-2000
			NZ 504936 A	27-09-2002
			PL 341212 A1	26-03-2001
			TR 200001737 T2	21-12-2000
			US 2003072768 A1	17-04-2003
			US 6500432 B1	31-12-2002
			ZA 9811501 A	15-06-2000
WO 9728818	A	14-08-1997	AT 225668 T	15-10-2002
			AU 724716 B2	28-09-2000
			AU 1800597 A	28-08-1997
			CA 2244110 A1	14-08-1997
			DE 69716240 D1	14-11-2002
			DE 69716240 T2	26-06-2003
			DK 880360 T3	27-01-2003
			EP 0880360 A1	02-12-1998
			ES 2184990 T3	16-04-2003
			WO 9728818 A1	14-08-1997
			JP 2000505802 T	16-05-2000
			PT 880360 T	28-02-2003
			US 2003100496 A1	29-05-2003
WO 0068259	A	16-11-2000	AU 4605100 A	21-11-2000
			CA 2372497 A1	16-11-2000
			EP 1175437 A2	30-01-2002
			WO 0068259 A2	16-11-2000
WO 9324148	A	09-12-1993	AP 567 A	25-11-1996
			AT 168271 T	15-08-1998
			AU 709406 B2	26-08-1999
			AU 1648097 A	29-05-1997
			AU 4315693 A	30-12-1993
			CA 2136429 A1	09-12-1993
			CN 1085450 A	20-04-1994
			CZ 9402892 A3	13-09-1995
			DE 69319728 D1	20-08-1998
			DE 69319728 T2	04-02-1999
			DK 642355 T3	30-11-1998
			WO 9324148 A1	09-12-1993
			EP 0642355 A1	15-03-1995
			EP 0835663 A2	15-04-1998
			ES 2118963 T3	01-10-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/03353

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9324148	A	FI 945483 A	20-01-1995
		HK 1011290 A1	28-04-2000
		HU 71791 A2	28-02-1996
		IL 105770 A	16-08-1998
		JP 7508267 T	14-09-1995
		MX 9302982 A1	01-12-1993
		NO 944475 A	18-01-1995
		NZ 253065 A	28-10-1996
		PL 174077 B1	30-06-1998
		RU 2160120 C2	10-12-2000
		SG 48365 A1	17-04-1998
		SI 9300271 A	31-12-1993
		SK 142194 A3	09-08-1995
		US 6013264 A	11-01-2000
		ZA 9303541 A	21-06-1994